• 1
    Chism DB,Hanlon AL,Horwitz EM,Feigenberg SJ,Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59: 380385.
  • 2
    D'Amico AV,Whittington R,Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969974.
  • 3
    Coen JJ,Zietman AL,Thakral H,Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002; 20: 31993205.
  • 4
    American Joint Committee on Cancer. Prostate. In: GreeneFL, PageDL, FlemingID, et al, eds. AJCC cancer staging manual. New York: Springer; 2002: 337345.
  • 5
    Hanks GE. The prostate. St. Louis: C.V. Mosby; 1989.
  • 6
    Horwitz EM,Hanlon AL,Pinover WH,Anderson PR,Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001; 92: 12811287.
  • 7
    Monti AF,Ostinelli A,Frigerio M, et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol. 1995; 35: 145150.
  • 8
    Cox J,Grignon D,Kaplan R,Parsons J,Schellhammer P. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 10351041.
  • 9
    Roach M3rd,Hanks G,Thames HJr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965974.
  • 10
    Horwitz EM,Thames HD,Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005; 173: 797802.
  • 11
    Kestin LL,Vicini FA,Martinez AA. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys. 2002; 53: 304315.
  • 12
    Pickles T,Kim-Sing C,Morris WJ,Tyldesley S,Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys. 2003; 57: 1118.
  • 13
    Vicini FA,Kestin LL,Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer. 2000; 88: 23052318.
  • 14
    Thames H,Kuban D,Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003; 57: 929943.
  • 15
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Statistical Assoc. 1958; 53: 447457.
  • 16
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 17
    Hanks GE,Hanlon AL,Epstein B,Horwitz EM. Dose response in prostate cancer with 8–12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002; 54: 427435.
  • 18
    Pollack A,Zagars GK,Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53: 10971105.
  • 19
    Zelefsky MJ,Fuks Z,Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166: 876881. Erratum in:J Urol.2001;166:1839.
  • 20
    Pollack A,Smith LG,von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000; 48: 507512.
  • 21
    Pollack A,Hanlon AL,Horwitz EM,Feigenberg SJ,Uzzo RG,Hanks GE. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol. 2004; 171: 11321136.
  • 22
    Kupelian PA,Elshaikh M,Reddy CA,Zippe C,Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002; 20: 33763385.
  • 23
    Amling CL,Blute ML,Bergstralh EJ,Seay TM,Slezak J,Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000; 164: 101105.
  • 24
    Rosser CJ,Levy LB,Kuban DA, et al. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate. J Urol. 2003; 169: 21602165.
  • 25
    Naya Y,Okihara K,Evans RB,Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology. 2005; 66: 350355.
  • 26
    Leventis AK,Shariat SF,Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology. 2001; 219: 432439.
  • 27
    Saleem MD,Sanders H,Abu El Naser M,El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology. 1998; 51: 283286.
  • 28
    Levegrun S,Jackson A,Zelefsky MJ, et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol. 2002; 63: 1126.
  • 29
    Pollack A,Zagars GK,Antolak JA,Kuban DA,Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002; 54: 677685.
  • 30
    Dugan TC,Shipley WU,Young RH, et al. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J Urol. 1991; 146: 13131316.
  • 31
    Peeters ST,Heemsbergen WD,Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24: 19901996.
  • 32
    Zietman AL,DeSilvio ML,Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 12331239.
  • 33
    Kuban D,Tucker S,Dong L, et al. Long-term results of a randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66( suppl): S8S9.
  • 34
    Morgan PB,Hanlon AL,Horwitz EM,Buyyounouski MK,Uzzo RG,Pollack A. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 10741081.
  • 35
    Ward JF,Sebo TJ,Blute ML,Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005; 173: 11561160.
  • 36
    Grado GL,Collins JM,Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999; 53: 210.
  • 37
    Bahn DK,Lee F,Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer. 2003; 2: 111114.
  • 38
    Albertsen PC,Hanley JA,Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293: 20952101.
  • 39
    Hanlon AL,Hanks GE. Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation. Urology. 2000; 55: 725729.